Top Analyst Reports for AbbVie, RTX & IBM

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• AbbVie faces several headwinds like Humira LOE impact, slowing oncology sales and continued macro headwinds for Aesthetics

  80% confidence

• DaVita's patient-centric care model leverages its platform and continued execution of targeted initiatives to improve treatment adherence is an added plus

  80% confidence

• RTX continues to receive ample orders for its wide range of combat-proven defense products from the Pentagon and its foreign allies

  80% confidence

• EVI's operating cash flow improved to $5.1 million despite a $12.6 million inventory build

  80% confidence

• Skyrizi and Rinvoq are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years

  80% confidence

• AbbVie's neuroscience portfolio is contributing to top-line growth

  80% confidence

• Weakness in IBM's traditional business and foreign exchange volatility remain concerns

  80% confidence

• Corcept's sole dependence on Cushing's syndrome drug, Korlym, for revenues is concerning

  80% confidence

• Boise Cascade is hurting due to slow single-family housing starts, resulting in low volumes and unfavorable commodity pricing

  80% confidence

• Supply-chain challenges continue to affect the aerospace sector, which may adversely impact RTX

  80% confidence

• IBM's focus on quantum technology for solutions to complex problems beyond the reach of classical computing is a tailwind

  80% confidence

• AbbVie has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq

  80% confidence

• IBM is gaining traction on the Watsonx platform, which is likely to be its core technology platform for AI capabilities

  80% confidence

• The uncertainties created by the recent imposition of U.S. government-issued import tariffs pose a risk for RTX

  80% confidence

• Rising expenses remain a concern for Affirm

  80% confidence

• Strong service and parts growth support Penske's earnings, though declining BEV units and softer premium demand may limit near-term results

  80% confidence

• AbbVie delivered robust net sales growth in 2025 which is just the second full year following the Humira LOE in the United States

  80% confidence

• IPG Photonics is benefiting from innovations such as the CROSSBOW laser counter-UAV system and growth in medical applications, particularly urology

  80% confidence

• Strength in hybrid cloud, AI-powered automation, and enterprise consulting is driving growth in IBM's Software and Consulting segment

  80% confidence

• AbbVie has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline that should drive long-term growth

  80% confidence

• EVI delivered solid top-line momentum, with revenues rising 24% in the December quarter and 20% for the first six months of FY26, alongside gross margin expansion to ~31%

  80% confidence

• Steadily improving global commercial air traffic boosts RTX's sales

  80% confidence

• Strong volumes and a favorable mix across large commercial engines and Pratt Canada operations are expected to support RTX's growth momentum in the commercial aerospace market

  80% confidence

• Rocky Mountain faces near-term liquidity and covenant risk, with $0.6 million cash, continued operating losses, high-cost 12% debt and reliance on external funding

  80% confidence

• Growth in Affirm's active merchant numbers and improvement in Gross Merchandise Value will fuel its top-line

  80% confidence

• LATAM Airlines is focused on premium traffic and an efficient cost structure

  80% confidence

• Spectrum Brands is focused on driving growth through brand-building, innovation and operating efficiency

  80% confidence

• Easing demand momentum amid persistent headwinds hurts Shake Shack with limited traffic growth, inflation pressures and weather disruptions remaining a concern

  80% confidence

• EVI's fiscal 2025 acquisitions contributed $40 million in revenues and $2 million in net income year to date

  80% confidence

• Improved mix, pricing discipline and operating leverage are enhancing EVI's earnings quality

  80% confidence